Table of Contents

company-logo

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.

CANbridge Pharmaceuticals Dividend Announcement

• CANbridge Pharmaceuticals does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on CANbridge Pharmaceuticals dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

CANbridge Pharmaceuticals Dividend History

CANbridge Pharmaceuticals Dividend Yield

CANbridge Pharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing CANbridge Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:

CANbridge Pharmaceuticals Financial Ratios

P/E ratio-0.14
PEG ratio-0.01
P/B ratio-0.21
ROE254.94%
Payout ratio0.00%
Current ratio0.24
Quick ratio0.21
Cash Ratio0.12

CANbridge Pharmaceuticals Dividend FAQ

Does CANbridge Pharmaceuticals stock pay dividends?
CANbridge Pharmaceuticals does not currently pay dividends to its shareholders.
Has CANbridge Pharmaceuticals ever paid a dividend?
No, CANbridge Pharmaceuticals has no a history of paying dividends to its shareholders. CANbridge Pharmaceuticals is not known for its dividend payments.
Why doesn't CANbridge Pharmaceuticals pay dividends?
There are several potential reasons why CANbridge Pharmaceuticals would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will CANbridge Pharmaceuticals ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While CANbridge Pharmaceuticals has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is CANbridge Pharmaceuticals a dividend aristocrat?
CANbridge Pharmaceuticals is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is CANbridge Pharmaceuticals a dividend king?
CANbridge Pharmaceuticals is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is CANbridge Pharmaceuticals a dividend stock?
No, CANbridge Pharmaceuticals is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy CANbridge Pharmaceuticals stocks?
To buy CANbridge Pharmaceuticals you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy CANbridge Pharmaceuticals stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.